HCG Q2 FY27: revenue up 16%, adjusted EBITDA rises 17%
India's HCG cancer hospital network reported 15.8% higher revenue and 17.2% higher adjusted EBITDA in Q2 FY2027, according to Moody's.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
HCG, India's largest dedicated cancer hospital network, lifted consolidated revenue from operations by 15.8% year on year to Rs 7,318 million in the quarter ended 30 September 2026, Moody's reported. Adjusted EBITDA climbed 17.2% to Rs 1,425 million, helped by more patients and higher revenue per patient.
For the first half of FY2027, revenue rose 14.6% to Rs 14,100 million and adjusted EBITDA grew 18.3% to Rs 2,740 million. The EBITDA margin widened to 19.7% from 18.8% a year earlier. Patient volumes increased 9%, average revenue per patient rose 7%, and international business revenue grew about 54% to Rs 302 million.
why it matters
For investors, this is a report on improving profitability: the company is growing through both volume and more complex oncology services, not only through new beds. Markets usually judge quarterly figures against analyst expectations, which the source does not provide.
market impact
HCG shares and India's healthcare sector: strong quarterly figures support investor interest.
- HCG shares pressure up — revenue and margin growth above last year's levels
tags
instruments
sources
- HCG Reports 16% Revenue Growth In Q2 FY27, Adjusted EBITDA Rises 17% — Moody's, 7 November 2026 at 09:00 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗